Johnson & Johnson (JNJ)vsVivos Therapeutics Inc (VVOS)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
VVOS
Vivos Therapeutics Inc
$0.18
+1.32%
HEALTHCARE · Cap: $3.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 468415% more annual revenue ($97.93B vs $20.90M). JNJ leads profitability with a 21.5% profit margin vs -121.8%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
VVOS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
-5.4%
Fair Value
$1.47
Current Price
$0.18
$1.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Revenue surging 34.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1600.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : VVOS
The strongest argument for VVOS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 34.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : VVOS
The primary concerns for VVOS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VVOS is a hypergrowth play — different risk/reward profiles.
VVOS carries more volatility with a beta of 6.00 — expect wider price swings.
VVOS is growing revenue faster at 34.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 31/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Vivos Therapeutics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?